Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

BACKGROUND: Alemtuzumab, an anti-CD52 monoclonal antibody, was administered to patients with RA between 1991 and 1994. We have followed a cohort of recipients since that time and previously reported significant delays in immune reconstitution. Here we report >20 years of follow-up data from this...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooles, Faye A. H., Anderson, Amy E., Drayton, Tracey, Harry, Rachel A., Diboll, Julie, Munro, Lee, Thalayasingham, Nishanthi, Östör, Andrew J. K., Isaacs, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170892/
https://www.ncbi.nlm.nih.gov/pubmed/27993172
http://dx.doi.org/10.1186/s13075-016-1188-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170892/
https://www.ncbi.nlm.nih.gov/pubmed/27993172
http://dx.doi.org/10.1186/s13075-016-1188-6

Ejemplares similares